Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Human Genome, Glaxo Lupus Drug Needs Longer Review

Don't Miss Out —
Follow us on:

Dec. 3 (Bloomberg) -- Human Genome Sciences Inc. and GlaxoSmithKline Plc’s Benlysta, the first new treatment for lupus in 52 years, needs more review by U.S. regulators before it may be approved for sale.

The Food and Drug Administration extended the deadline for a decision on Benlysta by three months, to March 10, the companies said today in a statement. Human Genome, based in Rockville, Maryland, submitted additional information to the agency after an advisory panel voted 13-2 in support of the drug at a Nov. 16 meeting, according to the statement.

Michael Yee, an analyst at RBC Capital Markets in San Francisco, said Dec. 1 that a delayed decision was likely given the timing of the advisory panel. Benlysta was given a six-month expedited review under an FDA program designed to speed access to novel medicines. If approved, sales of the medicine may exceed $2.1 billion by 2014, according to the average estimate of five analysts surveyed by Bloomberg.

About 5 million people worldwide, including 1.5 million Americans, have lupus. Benlysta prevents the production of antibodies that attack healthy cells, causing swelling, joint and muscle pain, rashes and fever.

Human Genome fell $1, or 3.9 percent, to $24.60 in extended trading on the Nasdaq Stock Market. American depositary receipts of London-based Glaxo, each representing two ordinary shares, dropped 2 cents, to $39.17.

To contact the reporter on this story: Catherine Larkin in Washington at clarkin4@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.